Colorectal cancer is the third leading cause of cancer-related deaths for both men and women in the United States, according to the American Cancer Society. Screening can save lives, but the rate of screening for colorectal cancer is low, less than 65 percent, which means thousands of people die unnecessarily every year. Peter H. Schwartz, MD, PhD, hopes to make an impact on that issue by using precision health, specifically by providing patients with information about their individual risk factors.
Precision Health News
Last month, faculty, staff and students at Indiana University School of Medicine learned that Anantha Shekhar, MD, PhD, executive associate dean for research affairs and principal investigator of the IU Grand Challenge Precision Health Initiative has been named the new dean of the University of Pittsburgh School of Medicine.
Researchers at IU School of Medicine have started collaborating with their community partners, RED Alliance and Pink 4 Ever, to eliminate disparity as part of the IU Precision Health Initiative (PHI) triple negative breast cancer study.
The IU Grand Challenge Precision Health Initiative will be showcased in front of Big Ten fans during the 2019-2020 basketball season.
The IU School of Medicine-Purdue University Alzheimer's Disease Drug Discovery Center (ADDD Center) held its kickoff workshop in November, bringing researchers together for the first time to set expectations for the next several years.
Testing people to understand more about their genetic information isn’t a new practice, but it’s part of a rapidly-changing pharmacology field. The second phase of NIH-funded network, “Implementing Genomics in Practice (IGNITE),” is underway at five locations across the country, including IU School of Medicine.
Clinical researchers at Indiana University School of Medicine are using personalized medicine to treat patients at the Precision Genomics clinic. The goal is to find drugs that work well on a patient's tumor, while also having fewer side effects.
Leaders with the RED Alliance and Pink-4-Ever say this new clinical trial is important for their community in Indiana, as well as nationwide.
Ken Cornetta, MD, has been named the leader for the cell, gene and immune therapy pillar of the Indiana University Grand Challenge Precision Health Initiative (PHI).
“It’s been said that developing a drug is not rocket science, it’s actually much, much harder,” said Dan Skovronsky, MD, PhD and Chief Scientific Officer for Eli Lilly and Company. In this month’s podcast, you will hear how medicines are discovered and made.